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Activation of epithelial-mesenchymal transition (EMT) is important for cancer cell dissemination. Two papers
in this issue of Cancer Cell (Ocan˜a and colleagues and Tsai and colleagues) support the concept that the
reversal of EMT is necessary for efficient metastatic colonization. Moreover, although EMT has been associ-
ated with stemness properties, one study indicates that they are not necessarily linked.Metastasis is responsible for more than
90% of cancer associated mortality;
therefore, the clinical need to prevent or
target metastasis is great. For distant
metastasis, primary tumor cells must
invade, disseminate through blood
vessels, seed at the distant site, and colo-
nize to macrometastases. De-differentia-
tion through aberrant activation of the
embryonic program ‘‘epithelial-mesen-
chymal transition’’ (EMT) was shown to
strongly enhance cancer cell motility and
dissemination (Thiery et al., 2009). More-
over, gene expression patterns in human
cancers indicated that de-differentiated
cancer cells combine EMT properties
with a stem-cell like phenotype, leading
to the concept of ‘‘migrating cancer
stem cells’’ as the basis of metastasis
(Brabletz et al., 2005). A direct molecular
link between EMT and stemness was
demonstrated by seminal findings that
EMT activators, such as Twist1, can co-
induce EMT and stemness properties
(Mani et al., 2008; Morel et al., 2008),
thereby linking the EMT and cancer
stem cell concept (Dalerba et al., 2007).
However, metastases of the most com-
mon human cancers (well- to moder-
ately-differentiated carcinomas) often
show a re-differentiation in the sense
of a mesenchymal-epithelial (re-)transi-
tion (MET). Consequently, transient de-
differentiation (EMT)- re-differentiation
(MET) processes were proposed to be
a driving force of metastasis (Brabletz
et al., 2001). But why do metastases re-
differentiate? Invasive, de-differentiated
cancer cells were shown to be growth
arrested, and proliferation was detected
in re-differentiated metastasis, leadingto the proposal that EMT must be
reversed in order to allow growth and
colonization (Brabletz et al., 2001). This
is supported by the fact that EMT-
inducing transcription factors can directly
inhibit proliferation (Thiery et al., 2009).
Although many clinical reports fostered
the concept of transient EMT-MET
switches in metastasis, there are only
a few experimental proofs (e.g., Chaffer
et al., 2006; Korpal et al., 2011). Two
papers in this issue of Cancer Cell sup-
port the role of an EMT in dissemination
and the need of a MET for efficient
metastasis.
In the first report, Tsai et al. (2012, in
this issue of Cancer Cell) used an elegant
mouse model for skin cancer in which
metastatic squamous cell carcinomas
were induced by topic application of
the carcinogens DBMA and TPA and
the expression of Twist1 was selectively
induced in keratinocytes by docycycline.
Oral application of doxycycline induced
Twist1 in all cancer cells, irrespective of
their localization (primary tumor, circu-
lating or disseminated tumor cells, or
metastasis), therefore modeling ‘‘irre-
versible’’ Twist1/EMT activation. In
contrast, topical application of doxycy-
cline only induced Twist1 in the primary
skin tumors, and Twist1 expression is
shut down in disseminated tumor cells
(‘‘reversible’’ Twist1/EMT activation).
Twist1 activation in both conditions
(compared to uninduced controls) in-
creased the number of circulating tumor
cells and tumor cells extravasated to
the lung, supporting the role of EMT in
dissemination. However, the number of
metastases in the ‘‘reversible’’ Twist1-Cancer Cell 22, Dmodel was higher than that in the ‘‘irre-
versible’’ Twist1-model. Moreover, the
authors demonstrated that downregula-
tion of Twist1 in metastases was associ-
ated with increased proliferation and
reversal of an EMT-associated growth
arrest. In summary, this study clearly
supports the role of an EMT in dissemi-
nation and the necessity of a subsequent
MET for colonization and macrometasta-
sis (Figure 1A). Twist1 downregulation
was shown to be important to overcome
EMT-associated growth arrest, but reac-
tivation of proliferation is likely not the
only reason for a MET in metastasis.
Recently, it was shown that, while re-
differentiation induced by expression of
miR-200 is required for metastatic
colonization in a xenograft model, miR-
200 also directly targets SEC23A, which
stimulates the secretion of metastasis-
suppressive proteins (Korpal et al.,
2011).
The second study by Ocana et al.
(2012, in this issue of Cancer Cell) also
supports the role of EMT for dissemina-
tion and the necessity to revert EMT for
metastasis. But, surprisingly, the features
of the newly discovered EMT activator
‘‘paired-related homeobox transcription
factor 1’’ (Prrx1) make the underlying
molecular links more complex. In contrast
to other EMT-activators, Prrx1 sup-
presses stemness traits, raising again
the questions of where and which are
the cancer stem cells. The authors de-
tected Prrx1 as an additional EMT inducer
activating delamination from the primitive
streak in chicken embryos. Prrx1 is coex-
pressed and cooperates with Twist1 in
inducing all EMT features relevant forecember 11, 2012 ª2012 Elsevier Inc. 699
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Figure 1. EMT and MET in Metastasis: Where Are the
Cancer Stem Cells?
Models and consequences deduced from the papers by Tsai
et al. (2012) and by Ocana et al. (2012) are shown.
(A) Data by Tsai et al. (2012) support the concept that upregu-
lation of an EMT activator (e.g., Twist1) in invasive cells of
the primary tumor induces dissemination. A downregulation
of the EMT inducer and a subsequent redifferentiation (MET)
at the distant site is necessary to allow colonization and
macrometastasis. Because Twist1 also induces stemness
properties and a growth arrest, putative cancer stem cells
are mobile but nonproliferating (migrating cancer stem cells;
green indicates stemness phenotype and activation).
(B) The EMT activator Prrx1, newly identified by Ocana et al.
(2012), suppresses stemness properties in the EMT and
dissemination state. Prrx1 must be downregulated to activate
stemness properties and allow colonization. Thus, putative
cancer stem cells are not mobile but embedded in the epithe-
lial tumor mass both in the primary tumor and metastases
(stationary cancer stem cells). Both types of metastasis
require an EMT for dissemination and a MET for colonization.
The most important difference is that in the Prrx1-type EMT,
growth arrest and stemness are uncoupled, favoring the
parallel maintenance of a MET, proliferation, and stemness
phenotype.
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and invasion. In a xenograft model
using human BT-549 breast cancer
cells (coexpressing Prrx1 and
Twist1), a knockdown of both
factors (but not of Twist1 alone!)
increased lung metastasis after tail
vein injection, but not in an ortho-
topic setting. Importantly, in con-
trast to the study by Tsai et al.
(2012), depletion of Twist1 alone
had no effect, indicating that Prrx1
is not only cooperating with Twist1,
but is also dominating its function.
The big surprise came when the
authors analyzed stemness and
tumor-initiating features: Prrx1 de-
creased stemness features and
knockdown of Prrx1 in BT-549-
increased mammosphere forma-
tion, self renewal capacity, and the
fraction of CD24low/CD44high cancer
stem cells. Of note, increased stem-
ness was associated with main-
tained proliferation capacity. This is
in contrast to stemness induced by
other EMT activators (Twist1 alone,
Snail1, Snail2, and ZEB1), which
are associated with a growth arrest.
Strikingly, the presence of Twist1
was not necessary for the stemness
features, because combined deple-
tion of both Prrx1 and Twist1 had
the same effect. Conversely, over-
expression of Prxx1 in another
undifferentiated breast cancer cell
line MDA-MB-231 (expressing
ZEB1 but neither Prrx1 nor Twist)
also suppressed stemness features,
indicating that ZEB1-associated
stemness can also be inhibited.Finally, by analyzing published data
sets, the authors could show that high
expression of Prrx1 (often associated
with Twist1 expression) in breast and the
squamous type of lung cancer is associ-
ated with a good prognosis and increased
metastasis-free survival. These results
are of high relevance for cancer biology
because they not only support the model
of an EMT/MET switch in metastasis, but
they also identify a potentially new mech-
anism allowing metastatic colonization by
uncoupling stemness from EMT and
growth arrest in favor of a parallel mainte-
nance of a stemness, MET, and prolifera-
tion phenotype (Figure 1B). In this con-
text, the study mechanistically supports
a concept where cancer stem cells either700 Cancer Cell 22, December 11, 2012 ª20can be embedded in the epithelial
mass of benign precoursors, primary
tumors, or metastases (stationary cancer
stem cells) or linked to EMT/motility in
invading, disseminating, growth-arrested
tumor cells (migrating cancer stem cells)
initially proposed from the analyses
of colon cancer (Brabletz et al., 2005)
(Figure 1).
However, these data on Prxx1 raise
a lot of new questions, particularly in the
context of publications on Twist1, e.g.,
by Tsai et al. (2012).
How do Twist and Prrx1 interact at
a molecular level and how does Prrx1
inhibit the stemness-inducing but not
the EMT-inducing function of Twist112 Elsevier Inc.(and potentially other EMT
inducers like Snail1 and ZEB1)?
How does the loss of Prrx1
induce stemness in (re-)dif-
ferentiated epithelial cancer
cells, which also downregulate
Twist1?
What is the role of Prxx1 in
physiological stem cell biology?
Does it distinguish between
stationary and migrating stem
cells? Are these mutually ex-
clusive modes of stemness? Is
the Twist1-mode or the Prrx1-
mode (Figure 1) more relevant
for human cancer metastasis?
In which (cancer) cells and
tissues is Prrx1 expressed and
potentially controlling other EMT
inducers (see BT549 versus
MDA-MB-231; different areas
during primitive streak delami-
nation)?
In summary, both papers ex-
perimentally support the need of a
re-differentiation (MET) for the
colonization and metastasis of dif-
ferentiated carcinomas and show
that one reason is the EMT-associ-
ated growth arrest. This has a
clinical impact for future thera-
peutic strategies against metas-
tasis. Inducing differentiation and
targeting EMT alone might be
counterproductive by activating
proliferation of disseminated cells;
it should be combined with therapy
against cycling cells, e.g., with
a standard chemotherapy. In addi-
tion, inhibiting MET, thereby main-taining dormancy and/or directly target-
ing the stem cell phenotype, wherever
it is located, could be a promising
strategy.
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In this issue of Cancer Cell, Kopp and colleagues report that pancreatic ductal cells are largely refractory to
the induction of pancreatic neoplasia. Whereas a rare ductal subpopulation may still prove capable of
neoplastic transformation, these findings refocus attention on acinar and other non-ductal cell types as initi-
ators of this deadly neoplasm.While malignant tumors of the pancreas
can display a variety of histologic forms,
the term ‘‘pancreatic cancer’’ is usually
synonymous with a pathological diag-
nosis of pancreatic ductal adenocarci-
noma (PDAC). As its name implies,
PDAC has long been presumed to arise
from pancreatic ductal epithelial cells.
Along with its noninvasive precursor, pan-
creatic intraepithelial neoplasia (PanIN),
these tumors typically display a distinctly
duct-like histology, and express markers
of ductal differentiation. As demonstrated
for other tumor types, however, tumor
histology is often misleading in deter-
mining tumor lineage, and work from
Kopp et al. (2012) published in this
issue of Cancer Cell reinforces the
disputed paternity of pancreatic ‘‘ductal’’
neoplasia.
Initial clues suggesting that non-ductal
cells might serve as effective cells of
origin for pancreatic ductal neoplasia
were provided by studies involving
transgenic misexpression of individual
oncogenes under the regulation of non-ductal promoter elements, in which a
subset of resulting tumors displayed
histologic resemblance to adult ductal
epithelium (Sandgren et al., 1991). How-
ever, these similarities were ultimately
proven to be only skin-deep, as additional
studies of PanIN and PDAC revealed
activation of transcriptional programs
typically observed in embyronic pancre-
atic epithelium, but not in differentiated
duct cells (Miyamoto et al., 2003; Park
et al., 2011).
With the advent of autochthonous
mouse models of pancreatic neoplasia,
more recent studies have interrogated
individual pancreatic cell types for the
ability to generate PanIN, based upon
Cre/lox-mediated activation of oncogenic
Kras. Initial seminal work in this arena
utilized either Pdx1Cre or Ptf1aCre alleles
to activate Kras in embryonic pancreatic
progenitor cells (Aguirre et al., 2003;
Hingorani et al., 2003). While these
studies demonstrated that embryonic
activation of oncogenic Kras effectively
initiated pancreatic ductal neoplasia,they provided considerably less informa-
tion regarding the capacity of individual
adult cell lineages to similarly serve as
effective cells of origin. Based on the
availability of appropriate Cre driver
lines, this adult capacity was first interro-
gated in pancreatic acinar cells. Using
either a Nestin-Cre driver to activate
oncogenic Kras in exocrine progenitor
cells and their acinar cell descendants
(Carrie`re et al., 2007) or a variety of induc-
ible Cre lines to activate Kras in adult
acinar cells (De La O et al., 2008; Guerra
et al., 2007; Habbe et al., 2008), these
studies provided strong evidence that
acinar cells could indeed serve as effec-
tive biologic parents for pancreatic ductal
neoplasia. In these studies, the ability of
adult acinar cells to generate PanIN was
dramatically accelerated in the context
of associated pancreatitis, a known risk
factor for the human disease. Additional
studies suggested that a permissive
inflammatory microenvironment could
broadly bestow PanIN-parenting capabil-
ities, as even insulin-expressing cellsecember 11, 2012 ª2012 Elsevier Inc. 701
